SubsidieMeestersPioneering diagnostics in dermatology and cancer
Dermagnostix aims to enhance dermatological diagnostics with a rapid, automated platform for precise molecular testing, reducing misdiagnoses and improving patient care.
Projectdetails
Introduction
At Dermagnostix, we envision the next level for molecular diagnostics in human skin to improve patients’ lives and clinical practice in dermatology.
Background
Skin diseases are the 4th most relevant human illnesses according to loss of quality of life. Conventional diagnostics in dermatology based on clinical view and histopathology are imprecise and subjective, resulting in up to 50% of misdiagnosed cases and insufficient or harmful therapies.
Technological Innovation
At Dermagnostix, we have developed a comprehensive technological platform for fast and objective molecular diagnostics in dermatology to reduce health care costs and improve patient treatment.
Key Features
- Our fully automated platform delivers results within 90 minutes.
- Testing can be run everywhere and at any time.
- Our easy-to-handle diagnostic device brings objective and precise skin diagnostics to reality.
- It allows simultaneous detection of up to 40 different molecular targets within one single test.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.000 |
| Totale projectbegroting | € 5.169.182 |
Tijdlijn
| Startdatum | 1-10-2022 |
| Einddatum | 30-9-2024 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- DERMAGNOSTIX GMBHpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Precision biomarker based on digital pathology and artificial intelligence to guide fast and cost-effective personalized treatment decision support for colorectal cancer patientsDoMore Dx offers innovative diagnostics software using deep learning on cancer tissue images to personalize chemotherapy decisions, potentially saving 250,000 patients and 4 billion EUR annually. | EIC Accelerator | € 2.499.999 | 2024 | Details |
SWAN: Blitzscaling the early detection of skin cancerSwan offers rapid, full-body dermoscopic skin cancer detection using advanced AI and imaging technologies, enhancing early diagnosis and treatment accessibility for all stakeholders. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Transforming Molecular Diagnostics through NanoTechnologyAltratech Ltd aims to revolutionize molecular diagnostics by using patented nanotechnology for rapid, non-clinical detection of viruses and pathogens without biological amplification. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Disruptive and high accuracy test for early colorectal cancer detection in bloodAMADIX aims to enhance early colorectal cancer detection through a novel blood test, PreveCol, integrating advanced biomarkers and AI-driven risk prediction, targeting commercialization by 2032. | EIC Accelerator | € 2.497.568 | 2022 | Details |
Precision biomarker based on digital pathology and artificial intelligence to guide fast and cost-effective personalized treatment decision support for colorectal cancer patients
DoMore Dx offers innovative diagnostics software using deep learning on cancer tissue images to personalize chemotherapy decisions, potentially saving 250,000 patients and 4 billion EUR annually.
SWAN: Blitzscaling the early detection of skin cancer
Swan offers rapid, full-body dermoscopic skin cancer detection using advanced AI and imaging technologies, enhancing early diagnosis and treatment accessibility for all stakeholders.
Transforming Molecular Diagnostics through NanoTechnology
Altratech Ltd aims to revolutionize molecular diagnostics by using patented nanotechnology for rapid, non-clinical detection of viruses and pathogens without biological amplification.
Disruptive and high accuracy test for early colorectal cancer detection in blood
AMADIX aims to enhance early colorectal cancer detection through a novel blood test, PreveCol, integrating advanced biomarkers and AI-driven risk prediction, targeting commercialization by 2032.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
SkinSight360SkinSight360 onderzoekt de haalbaarheid van AI-gedreven dermatologische zorg en verbetert de communicatie tussen patiënten en dermatologen. | Mkb-innovati... | € 20.000 | 2024 | Details |
Digital Skintyping Platform based on dermoscopy & AII-Parse ontwikkelt een digitaal platform dat AI gebruikt om huidtype te analyseren via dermatoscoopbeelden, met als doel het risico op huidkanker te verminderen en monitoring te verbeteren. | Mkb-innovati... | € 18.888 | 2022 | Details |
Uitbreiding methylatie platformsMLA Dx ontwikkelt een prognostische methode voor vroeg stadium melanomen via LY75 methylatie, ter verbetering van diagnose en behandeling. | Mkb-innovati... | € 20.000 | 2021 | Details |
Leveraging CRISPR-Cas for fast and accurate point-of-care diagnosticsScope Biosciences aims to validate its patented CRISPR-Cas diagnostic technology, scopeDx, for rapid, accurate, and adaptable point-of-care diagnostics in healthcare. | EIC Transition | € 2.498.125 | 2024 | Details |
Ontwikkeling van innovatieve prognostische melanoomtestDit project ontwikkelt en valideert een innovatieve prognostische melanoomtest gebaseerd op methylatie van het LY75 gen voor bredere klinische toepassing. | Mkb-innovati... | € 165.130 | 2020 | Details |
SkinSight360
SkinSight360 onderzoekt de haalbaarheid van AI-gedreven dermatologische zorg en verbetert de communicatie tussen patiënten en dermatologen.
Digital Skintyping Platform based on dermoscopy & AI
I-Parse ontwikkelt een digitaal platform dat AI gebruikt om huidtype te analyseren via dermatoscoopbeelden, met als doel het risico op huidkanker te verminderen en monitoring te verbeteren.
Uitbreiding methylatie platforms
MLA Dx ontwikkelt een prognostische methode voor vroeg stadium melanomen via LY75 methylatie, ter verbetering van diagnose en behandeling.
Leveraging CRISPR-Cas for fast and accurate point-of-care diagnostics
Scope Biosciences aims to validate its patented CRISPR-Cas diagnostic technology, scopeDx, for rapid, accurate, and adaptable point-of-care diagnostics in healthcare.
Ontwikkeling van innovatieve prognostische melanoomtest
Dit project ontwikkelt en valideert een innovatieve prognostische melanoomtest gebaseerd op methylatie van het LY75 gen voor bredere klinische toepassing.